Press Releases

SAN FRANCISCO--(BUSINESS WIRE)-- New Relic, the all-in-one observability platform for every engineer, announced Katrina Wong as the company’s next Chief Marketing Officer. Wong will oversee the company’s brand, demand, and communications initiatives with a focus on driving growth and market expansion.

Wong brings over 20 years of experience in marketing, go-to-market, and community development to New Relic. She has a proven track record for launching products... (continue reading...)

LOS ANGELES, May 06, 2024 (GLOBE NEWSWIRE) --  A team of top media executives have joined forces to announce the launch of Fixated, a company aimed at elevating the fragmented digital entertainment landscape by providing a one-stop-shop for creators, fans, and brands.

The team brings together an executive bench of creator-economy all stars with diverse and complementary backgrounds that include a deep-rooted understanding and expertise of virality and... (continue reading...)

Findings From These Studies Could Save Thousands of Lives Through Better Understanding the Mechanistic Basis of Chronic Wound Infection

ORLANDO, FL / ACCESSWIRE / May 6, 2024 / MicroGenDX, a global leader in next-generation sequencing (NGS) diagnostics of infection, and members from the academic lab of Caleb Phillips at Texas Tech University (TTU) will present four groundbreaking oral presentations at the Wound Healing Society meeting in May 2024. Based on the microbial... (continue reading...)

Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information,... (continue reading...)

EDINBURGH, Scotland, May 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,750,000 of the Company's American Depositary Shares (the "ADSs") originally issued in... (continue reading...)